Investors.harrow.com

Investor Relations Harrow, Inc.

WEBHarrow, Inc. (NASDAQ: HROW) is an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative …

Actived: 9 days ago

URL: https://investors.harrow.com/

Harrow Health Launches New Corporate and Investor Website

WEBNASHVILLE, Tenn., June 01, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused …

Category:  Health Go Health

Harrow Health Announces First Quarter 2022 Financial Results

WEBSeventh Consecutive Quarter of Record Results. Highlights for First Quarter 2022: Record revenues of $22.1 million, up 43% over $15.4 million for the prior-year …

Category:  Health Go Health

Harrow Health, Inc. Changes Corporate Name to Harrow, Inc.

WEBNASHVILLE, Tenn.--(BUSINESS WIRE)--Sep. 29, 2023-- Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced that effective …

Category:  Health Go Health

Harrow Health Acquires Patented Ophthalmic Surgical Drug …

WEBNew Drug Application Expected to Be Filed in Late 2021. NASHVILLE, Tenn. & MENDRISIO, Switzerland--(BUSINESS WIRE)--Jul. 27, 2021-- Harrow Health, Inc. …

Category:  Health Go Health

Executive Management Harrow, Inc.

WEBMARK L. BAUM. Chief Executive Officer and Chairman of the Board of Directors. Mark L. Baum is the founder, Chairman of the Board, and CEO of Harrow. For the 2014-2017 …

Category:  Health Go Health

Harrow Announces U.S. FDA Approval of IHEEZO™ …

WEBIHEEZO™ Represents the First Approved Use in the U.S. Ophthalmic Market of Chloroprocaine Hydrochloride and the First Branded Ocular Anesthetic …

Category:  Health Go Health

Harrow Announces Fourth Quarter and Year-End 2022 Financial …

WEBHarrow Announces Fourth Quarter and Year-End 2022 Financial Results. March 23, 2023 at 4:06 PM EDT. PDF Version. 2022 and Recent Highlights: Full-year …

Category:  Health Go Health

Board of Directors Harrow, Inc.

WEBMARK L. BAUM. Chief Executive Officer and Chairman of the Board of Directors. Mark L. Baum is the founder, Chairman of the Board, and CEO of Harrow. For the 2014-2017 …

Category:  Health Go Health

Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE

WEBVEVYE® is the First and Only Cyclosporine-Based Product Indicated for the Treatment of Both Signs and Symptoms of Dry Eye Disease with Efficacy Demonstrated …

Category:  Health Go Health

Harrow Announces First Quarter 2023 Financial Results Harrow, Inc.

WEBBased on our results to date, we are reaffirming our 2023 guidance of $135 million to $143 million in net revenues and $44 million to $50 million in adjusted EBITDA. …

Category:  Health Go Health

Harrow Acquires Santen’s Branded Ophthalmic Portfolio

WEBHarrow Health, Inc. (Nasdaq: HROW) is a leading U.S. eyecare pharmaceutical company engaged in the discovery, development, and …

Category:  Health Go Health

Harrow Enters into Agreement to Acquire Exclusive

WEBNASHVILLE, Tenn.--(BUSINESS WIRE)--Dec. 14, 2022-- Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, …

Category:  Health Go Health

Harrow Health Announces Appointments to Its Board of Directors

WEBNASHVILLE, Tenn.--(BUSINESS WIRE)--Mar. 31, 2022-- Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, today announced …

Category:  Health Go Health

Harrow Announces Proposed Offering of $100 Million

WEBNASHVILLE--(BUSINESS WIRE)--Dec. 14, 2022-- Harrow Health, Inc. (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the …

Category:  Health Go Health

Press Releases Harrow, Inc.

WEBApril 25, 2024. Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024. April 2, 2024. Melt Pharmaceuticals Closes $24 Million …

Category:  Health Go Health